MXPA05013220A - Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus tipo 2. - Google Patents

Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus tipo 2.

Info

Publication number
MXPA05013220A
MXPA05013220A MXPA05013220A MXPA05013220A MXPA05013220A MX PA05013220 A MXPA05013220 A MX PA05013220A MX PA05013220 A MXPA05013220 A MX PA05013220A MX PA05013220 A MXPA05013220 A MX PA05013220A MX PA05013220 A MXPA05013220 A MX PA05013220A
Authority
MX
Mexico
Prior art keywords
diabetes mellitus
treating diabetes
mellitus type
combined
pharmaceutical compositions
Prior art date
Application number
MXPA05013220A
Other languages
English (en)
Inventor
Victor Guillermo Alvarez Ochoa
Josefina Santos Murillo
Ma Elena Garcia Armenta
Original Assignee
Leopoldo De Jesus Espinosa Abdala
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leopoldo De Jesus Espinosa Abdala filed Critical Leopoldo De Jesus Espinosa Abdala
Priority to MXPA05013220A priority Critical patent/MXPA05013220A/es
Priority to EP06769371A priority patent/EP1958636A1/en
Priority to PCT/MX2006/000060 priority patent/WO2007067027A1/es
Priority to BRPI0619616-0A priority patent/BRPI0619616A2/pt
Publication of MXPA05013220A publication Critical patent/MXPA05013220A/es
Priority to EC2008008507A priority patent/ECSP088507A/es
Priority to CR10053A priority patent/CR10053A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Abstract

La presente invencion describe una composicion farmaceutica que comprende una combinacion de sustancias antidiabeticas como una sulfonilurea como lo es la Glimepirida y una tiazolidinediona como lo es la Pioglitazona para el uso farmacologico de la composicion en el tratamiento de la Diabetes Mellitus tipo 2; la composicion produce un producto de combinacion con propiedades mejoradas y produce un efecto sinergico. En resumen es una composicion farmaceutica sinergica que comprende una combinacion sinergica de una sulfonilurea y una tiazolidinediona para el tratamiento de la Diabetes Mellitus tipo 2, en la cual la sulfonilurea es la Glimepirida y/o cualquier de sus sales y la Tiazolidinediona es la Pioglitazona y/o cualquier de sus sales.
MXPA05013220A 2005-12-06 2005-12-06 Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus tipo 2. MXPA05013220A (es)

Priority Applications (6)

Application Number Priority Date Filing Date Title
MXPA05013220A MXPA05013220A (es) 2005-12-06 2005-12-06 Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus tipo 2.
EP06769371A EP1958636A1 (en) 2005-12-06 2006-06-23 Pharmaceutical compositions containing combined antidiabetic substances for use in type 2 diabetes mellitus
PCT/MX2006/000060 WO2007067027A1 (es) 2005-12-06 2006-06-23 Composiciones farmacéuticas que comprenden sustancias anti diabéticas combinadas para su uso en diabetes mellitus tipo 2
BRPI0619616-0A BRPI0619616A2 (pt) 2005-12-06 2006-06-23 composições farmacêuticas que compreendem substáncias antidiabéticas combinadas para seu uso em diabetes mellitus tipo 2
EC2008008507A ECSP088507A (es) 2005-12-06 2008-06-06 Composiciones farmacéuticas que comprenden sustancias antidiabéticas combinadas para su uso en diabetes mellitus tipo 2
CR10053A CR10053A (es) 2005-12-06 2008-06-06

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MXPA05013220A MXPA05013220A (es) 2005-12-06 2005-12-06 Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus tipo 2.

Publications (1)

Publication Number Publication Date
MXPA05013220A true MXPA05013220A (es) 2007-06-05

Family

ID=38123117

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05013220A MXPA05013220A (es) 2005-12-06 2005-12-06 Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus tipo 2.

Country Status (6)

Country Link
EP (1) EP1958636A1 (es)
BR (1) BRPI0619616A2 (es)
CR (1) CR10053A (es)
EC (1) ECSP088507A (es)
MX (1) MXPA05013220A (es)
WO (1) WO2007067027A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US20040147564A1 (en) * 2003-01-29 2004-07-29 Rao Vinay U. Combinations of glimepiride and the thiazolidinedione for treatment of diabetes
CN1874774B (zh) * 2003-10-31 2011-04-13 武田药品工业株式会社 包含胰岛素致敏剂、胰岛素促分泌素和聚氧乙烯脱水山梨醇脂肪酸酯的固体制剂

Also Published As

Publication number Publication date
BRPI0619616A2 (pt) 2011-10-04
CR10053A (es) 2008-08-06
EP1958636A1 (en) 2008-08-20
ECSP088507A (es) 2008-07-30
WO2007067027A1 (es) 2007-06-14

Similar Documents

Publication Publication Date Title
CL2006003672A1 (es) Compuestos derivados de pirimido-[4,5-b]-oxazinas; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de diabetes mellitus y/u obesidad.
WO2007111864A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2007136577A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
UA96308C2 (ru) Антагонисты рецептора глюкагона, композиция, которая содержит такие соединения, и их применение
BRPI0619153A8 (pt) derivados de 4-aminopirroltriazina substituída, e composição farmacêutica
WO2009137391A3 (en) Benzene sulfonamide thiazole and oxazole compounds
MX2009003741A (es) Composiciones liquidas de calcogenuro y metodos para fabricar y utilizar las mismas.
PL1965798T3 (pl) Użyteczne antybiotyki monobaktamowe
IL196543A (en) Pyridazinone derivatives, pharmaceutical preparations containing them for use in the treatment of disorders
EP1756074A4 (en) 1,2,4-OXADIAZOLE DERIVATIVES AS INHIBITORS OF DIPEPTIDYLPEPTIDASE-IV IN THE TREATMENT OR PREVENTION OF DIABETES
WO2007082808A3 (en) Thiazoles as 11 beta-hsd1 inhibitors
TW200722100A (en) A therapeutic agent for a β related disorders
WO2007017145A3 (en) Gsk-3 inhibitors
CL2007001006A1 (es) Compuestos derivados de piperidina u 8-aza-biciclo[3.2.1]octano sustituidos; formulacion farmaceutica; producto; y uso para el tratamiento o prevencion de enfermedades tales como diabetes mellitus no insulino dependiente, artritis, obesidad, dislipid
WO2006116148A3 (en) (7-arlysubstituted 2, 3-dihydr0-1-benz0furan-2-yl) alkylamines in the treatment' of substance abuse
ZA200802454B (en) Use of thienopyridone derivatives as AMPK activators and pharmaceutical compositions containing them
TW200732296A (en) Novel compounds
WO2008013840A3 (en) Erastin analogs and uses thereof
JO2578B1 (en) Compounds Theophene benzimidazole
NZ595314A (en) PHARMACEUTICAL COMPOSITIONS comprising (1S)-1,5-anhydro-1-[5-(4-ethoxybenzy1)-2-methoxy-4- methylpheny1]-1-thio-D-glucitol or a pharmaceutically acceptable salt thereof or a hydrate of the compound or the salt; and metformin.
CL2007001530A1 (es) Compuestos derivados de tiazol, inhibidores de fbpasa; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento y/o profilaxis de diabetes mellitus tipo i, ii y iii, desequilibrio de glucosa en ayunas, desequilibrio en la tolerancia de la glucosa y complicaciones de la diabetes.
WO2007006521A3 (en) Nutritional mixtures with a high and increased efficacy
WO2006128847A3 (en) Medicament containing a betamimetic in conjunction with an anticholinergic and a pde iv inhibitor
WO2007068473A3 (en) Organic compounds
WO2007047431A3 (en) Sulfonyl-substituted aryl compounds as modulators of peroxisome proliferator activated receptors

Legal Events

Date Code Title Description
GB Transfer or assignment

Owner name: WORLD-TRADE IMPORT-EXPORT, WTIE, AG.*

FA Abandonment or withdrawal